- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novartis Hires Patrick Horber as President, International
Appointment comes amid resignation of Marie-France Tschudin from company executive committee.
Effective Sept. 15, Marie-France Tschudin, president, innovative medicines international, chief commercial officer, will be leaving Novartis. In her place, the company has added Patrick Horber with the title of president, international. Currently, Horber works as SVP and president, immunology, AbbVie.
A native of Switzerland with an MD from the University of Zurich, Horber will join Novartis with over 20 years of experience in the biopharma field.
"As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress,” said Horber, in a company press release. “I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”
Reference: Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis. Novartis. September 6, 2023. Accessed September 6, 2023. https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
